Stock profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332.SS)

Country: ChinaSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: SHH
P/E TTM
11.8
History
P/E NTM
11.5
Market cap
36.4B
Currency CNY
KvantraRanki46
Value89
Quality25
Momentum6
Current price
21.51+0.09%
Benchmarks

No price history available.

Key financial summary

Financials in CNY
202020212022202320242025TTM2026E
Total revenueCNYm61,67469,01470,78875,51574,99377,445N/AN/A
Operating profitCNYmLockedLockedLockedLockedLockedLockedLockedLocked
Net profitCNYm2,9153,7203,9674,0562,8352,983N/AN/A
EPS reportedCNYLockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per shareCNYLockedLockedLockedLockedLockedLockedLockedLocked
Capex per shareCNYLockedLockedLockedLockedLockedLockedLockedLocked
FCF per shareCNYLockedLockedLockedLockedLockedLockedLockedLocked
Free cash flowCNYmLockedLockedLockedLockedLockedLockedLockedLocked
Net debtCNYmLockedLockedLockedLockedLockedLockedLockedLocked
Book value equityCNYmLockedLockedLockedLockedLockedLockedLockedLocked
Book value per shareCNYLockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)CNYLockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in CNY
202020212022202320242025TTM2026E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLocked

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Company overview

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL), along with its various subsidiaries, operates as a comprehensive pharmaceutical enterprise. It is actively engaged in the research, development, production, and distribution of a wide array of products, including traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials, natural and biological medications, and chemical raw material intermediates. Its operations span both the People's Republic of China and international markets. The company structures its extensive operations into four primary segments: Great Southern TCM, Great Commerce, Great Health, and a miscellaneous 'Others' category. Beyond its core pharmaceutical manufacturing, GBPHCL's activities extend to the wholesale, retail, import, and export of both Western and traditional Chinese medicines, as well as medical apparatus and instruments. Furthermore, its diverse product portfolio encompasses the research, development, production, and sale of consumer health items such as beverages, various food products (including pre-packaged items and dairy), and a broad range of pharmaceutical formulations like tablets, capsules, lozenges, injections, and even traditional specialties like tortoise herb jelly. The group also strategically invests in the broader health industry, focusing on areas like medical care, health management, health preservation, and elderly care. Complementing these activities, it offers commercial and advertising services. As of December 31, 2021, GBPHCL maintained a substantial retail presence, operating 154 chain pharmacy outlets. This network comprised 22 Cai Zhi Lin pharmacies, 36 Jian Min pharmacies, 51 GPC Prescription Pharmacy locations, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd. outlets, alongside an additional 22 general retail stores. Tracing its origins back to its incorporation in 1997, the company was initially known as Guangzhou Pharmaceutical Company Limited. It adopted its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. The company is headquartered in Guangzhou, China.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryChina
Trades inCNY

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SS)

600332.SS · SHH · Healthcare
21.51+0.09%
Sign up to track this stock

No price history available.

KvantraRank46
P/E TTM11.8
P/E NTM11.5
Market cap36.4B
KvantraRank46 / 100
Value
89
Quality
25
Momentum
6
Financialsin CNY
20242025TTM2026E
Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

About

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL), along with its various subsidiaries, operates as a comprehensive pharmaceutical enterprise. It is actively engaged in the research, development, production, and distribution of a wide array of products, including traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials, natural and biological medications, and chemical raw material intermediates. Its operations span both the People's Republic of China and international markets. The company structures its extensive operations into four primary segments: Great Southern TCM, Great Commerce, Great Health, and a miscellaneous 'Others' category. Beyond its core pharmaceutical manufacturing, GBPHCL's activities extend to the wholesale, retail, import, and export of both Western and traditional Chinese medicines, as well as medical apparatus and instruments. Furthermore, its diverse product portfolio encompasses the research, development, production, and sale of consumer health items such as beverages, various food products (including pre-packaged items and dairy), and a broad range of pharmaceutical formulations like tablets, capsules, lozenges, injections, and even traditional specialties like tortoise herb jelly. The group also strategically invests in the broader health industry, focusing on areas like medical care, health management, health preservation, and elderly care. Complementing these activities, it offers commercial and advertising services. As of December 31, 2021, GBPHCL maintained a substantial retail presence, operating 154 chain pharmacy outlets. This network comprised 22 Cai Zhi Lin pharmacies, 36 Jian Min pharmacies, 51 GPC Prescription Pharmacy locations, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd. outlets, alongside an additional 22 general retail stores. Tracing its origins back to its incorporation in 1997, the company was initially known as Guangzhou Pharmaceutical Company Limited. It adopted its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. The company is headquartered in Guangzhou, China.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryChina
Trades inCNY

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans